Medicine Grand Rounds – The 2024 Blount Distinguished Lectureship - STEM CELLS & GENOMICS: FROM PRECISION MEDICINE TO CLINICAL TRIALS IN DISH

Joseph C. Wu, MD, PhD is Director of Stanford Cardiovascular Institute and President of the American Heart Association.

Dr. Wu received his MD from Yale University and PhD (Molecular & Medical Pharmacology) at University of California, Los Angeles. He is board certified in cardiovascular medicine.

His lab works on cardiovascular genomics and induced pluripotent stem cells (iPSCs). The main goals are to (i) understand basic disease mechanisms, (ii) accelerate drug discovery via “clinical trial in a dish” concept, and (iii) implement precision medicine for patients. Dr. Wu has published >600 manuscripts with H-index of 133 on Google scholar. He is listed as top 0.1% of highly cited researchers by Web of Science for past 6 years (2018-2023).

Dr. Wu has received several awards, including the NIH Director’s New Innovator Award, NIH Roadmap Transformative Award, Presidential Early Career Award for Scientists and Engineers (PECASE) given out by President Obama at the White House, American Heart Association (AHA) Distinguished Scientist Award, AHA Merit Award, and Burroughs Wellcome Foundation Innovation in Regulatory Science Award. Dr. Wu serves on the FDA Cellular, Tissue, and Gene Therapies Advisory Committee. He is on the Board of the Keystone Symposia and American Heart Association.

Dr. Wu is an elected member of American Society for Clinical Investigation (ASCI), Association of University Cardiologists (AUC), American Institute for Medical and Biological Engineering (AIMBE), American Association for the Advancement of Science (AAAS), American Association of Physicians (AAP), Academia Sinica (Taiwan), National Academy of Inventors (NAI), and National Academy of Medicine (NAM).

Join us in person! Bruce Schroffel Auditorium, University of Colorado Hospital, Anschutz Inpatient Pavilion 2, First Floor Conference Room – Lunch Provided
or via Zoom.

Learning Objectives:

• Understand how stem cells can be used to elucidate cardiovascular disease mechanism
• Understand how drug discovery can be accelerated using patient-specific stem cells
• Understand how AI can be used to define drug target

Accreditation & Designation Statement: The University of Colorado School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Colorado School of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 MOC point in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Disclosure Statement: Dr Wureports a relevant financial relationship as a consultant for Takeda and Eli Lilly. All of the relevant financial relationships listed for these individuals have been mitigated. All of the other planners, faculty or individuals in control of content for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies, whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.